Volition's goal is to make its non-invasive cancer blood tests as common and simple to use as existing diabetic and cholesterol tests on similar formats.
Nucleosomics, Hypergenomics, Endometriosis


We believe current cancer diagnostic tests are inadequate: there is only one blood test for cancer (the PSA for prostate cancer) in common clinical use. 

Volition aims to address the need for inexpensive, accurate, and scalable cancer diagnostics with its NuQ® suite of products. NuQ® is based on proprietary Nucleosomics® technology: measurement and identification of nucleosome structures in the blood.

VolitionRX Limited is quoted on the OTC Bulletin Board in the United States of America under the symbol VNRX.


Colorectal Cancer

VolitionRx is currently in clinical trials for its diagnostic and screening tests for colorectal cancer. We are currently carrying out the following trials:

  • A 4800-patient independent trial in Denmark, designed to finalize VolitionRx's colorectal cancer diagnostic test panel
  • A prospective 250-patient trial in Belgium, designed to validate the technology; as well as to establish whether Nucleosomics can be used as a marker for chemotherapy efficacy
  • A 6000-patient independent screening trial in Denmark, to begin in 2014
Print E-mail

VolitionRx NuQ® Blood Test Detects 84% of Colorectal Cancers; Including Both Early- and Later-stage Cancers

Topline Data from 1,000-Subject Independent Blinded Trial to be Presented 9am PT Today during Aegis Capital 2014 Healthcare & Technology Conference; webcast at volitionrx.com

NAMUR, Belgium, September 11, 2014 /PRNewswire/ -- VolitionRx Limited (OTCQB: VNRX), a life sciences company focused on developing blood-based diagnostic tests for a broad range of cancer types, today announced that CEO Cameron Reynolds will this morning present topline data from its 4,800-subject colorectal cancer trial at Hvidovre Hospital, Copenhagen, Denmark. Mr. Reynolds will present data from an initial representative 938-subject sample, demonstrating that the Company is able to correctly diagnose 84% of colorectal cancers, including early-stage cancers, using its NuQ® blood-based diagnostic platform.


Recent Tweets

Aegis Capital Corp Healthcare Presentation

Aegis Capital Healthcare & Technology Conference – Thursday, September 11, 2014 9:00 a.m. PDT

Learn more


Copyright © 2011 VolitionRX. All Rights Reserved
VolitionRx - Singapore - 1 Scotts Road - #24-05 Shaw Centre - Singapore 228208
VolitionRx - Belgium - Centre Technologique - Rue du Séminaire, 20A - B-5000 Namur - Belgium